<DOC>
	<DOCNO>NCT01529619</DOCNO>
	<brief_summary>This multicenter study evaluate efficacy , safety tolerability Rivastigmine patch patient mild moderate Alzheimer 's disease switch Cholinesterase Inhibitors .</brief_summary>
	<brief_title>Efficacy , Safety Tolerability Rivastigmine Patch Patients With Mild Moderate Alzheimer 's Disease Switched From Cholinesterase Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>A diagnosis dementia Alzheimer 's type accord DSMIV criterion A clinical diagnosis probable AD accord NINCDS/ADRDA criterion An MMSE score &gt; = 10 &lt; = 23 Continuous treatment donepezil ≤ 5 mg/day galantamine ≤ 24 mg/day 4 week prior baseline visit Patients difficulty treat orally ChE inhibitor ( donepezil galantamine ) judge investigator . Difficulties define : Inadequate compliance ChE inhibitor screen baseline Presence caregiver 's burden administering drug orally screen baseline Inadequate treatment ( efficacious dose reach inadequate compliance ) ChE inhibitor adverse event screen baseline Patients swallow difficulty screen baseline A current DSMIV diagnosis major depression Taken rivastigmine past A score &gt; 5 Modified Hachinski Ischemic Scale ( MHIS ) Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Rivastigmine</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>Transdermal patch</keyword>
</DOC>